Advertisement

Document › Details
Pharmalink AB. (8/24/17). "Press Release: Thomas Eklund New Chairman of Pharmalink". Stockholm.
![]() |
Organisation | Pharmalink AB |
Today | Calliditas Therapeutics AB | |
Group | Calliditas Therapeutics AB | |
Organisation 2 | Investor Growth Capital | |
Group | Investor AB (Wallenberg) (Group) | |
![]() |
Product | Nefecon® |
Product 2 | finance | |
![]() |
Person | Eklund, Thomas (Investor Growth Capital + Alfred Berg ABN AMRO Capital Investment + Handelsbanken) |
Person 2 | Julander, Bengt (Pharmalink –201708 Board Chairman LEFT 8/17) | |
The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Thomas Eklund as new Chairman of the board.
Thomas Eklund joined the board on August 15, 2017.
“We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy. Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team”, said Bengt Julander, founder and outgoing Chairman of Pharmalink.
Thomas has extensive experience from the pharmaceutical and medtech industry, as well as the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital AB. Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma AB and Itrim AB, and board member of Boule Diagnostics AB, Biotage AB, Neoventa Medical AB, Memira AB, and Rodebjer Form AB.
Record changed: 2017-08-30 |
Advertisement

More documents for Calliditas Therapeutics AB
- [1] Calliditas Therapeutics AB. (1/8/19). "Press Release: Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America"....
- [2] Calliditas Therapeutics AB. (11/20/17). "Press Release: Surrogate Marker and Design of Calliditas Therapeutics’ IgA Nephropathy Phase 3 Study Agreed with the FDA". Stockholm....
- [3] Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics"....
- [4] Pharmalink AB. (8/15/17). "Press Release: Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications". Stockholm....
- [5] Pharmalink AB. (10/4/13). "Press Release: Pharmalink Raises SEK96 Million to Undertake Pivotal Studies with Lead Programs in Cancer Therapy and Renal Disease". Stockholm....
- [6] Pharmalink AB. (10/29/12). "Press Release: Pharmalink AB Strengthens Senior Management Team. Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development". Stockholm....
- [7] Pharmalink AB. (1/4/12). "Press Release: Pharmalink AB Raises SEK 35 Million through Share Issue". Stockholm....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top